Preceptorship on Advances in Multiple Sclerosis (MS) and Neuro-Myelitis Optica (NMO)6-8 July 2015 - Vancouver, Canada

FINAL PROGRAMME

General information

VenueThis live educational course takes place at the:University of British ColumbiaVancouver, Canada

LanguageThe official language of this live educational course is English.

Scientific secretariatEXCEMED - Excellence in Medical EducationSalita di San Nicola da Tolentino, 1/b00187 Rome, Italy

Programme and Relations Manager, Neurology and Oncology: Serena Dell’AricciaT: +39 06 420413 251F: +39 06 420413 677E-mail: info@excemed.org

Specialist Medical Advisor: Doriana Landi

EXCEMED is a Swiss Foundation with headquarters in 14, Rue du Rhône, 1204 Geneva, Switzerland

Organising secretariatMeridiano Congress International Via Sapri, 6 - 00185 Rome, ItalyCongress Manager: Concetta Di PalmaT +39 06 88 595 226 - F +39 06 88595 234E-mail: concetta.dipalma@meridiano.it

1

follow us onEXCEMED_Neuro

http://twitter.com/EXCEMED_Neuro#NMO

Preceptorship onAdvances in Multiple Sclerosis (MS) and Neuro-Myelitis Optica (NMO)

EXCEMED live educational course:

Preceptorship onAdvances in Multiple Sclerosis (MS) and Neuro-Myelitis Optica (NMO)6-8 July 2015 - Vancouver, Canada

AimThe emerging basic science and clinical breakthroughs in MS and NMO are transforming patient care. Clinicians caring for thispatient population need a strong understanding of latest treatments, diagnostic criteria and other exciting developments. This liveeducational course offers a comprehensive review of MS and NMO diagnosis, treatment and science with lectures by worldrenowned experts.

Learning objectivesBy attending this live educational course participants will be able to:• Acquire an advanced understanding of progressive MS and opportunities for repair• Apply and manage a comprehensive approach to clinical decision making with the complex range of MS therapies• Select and apply the new diagnostic criteria for NMO and treatment approaches for the management of Neuromyelitis Optica

(NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Target audienceClinicians and scientists currently involved in MS and/or NMO management.

AccreditationThis event is an Accredited Group Learning Activity eligible for up to 17.5 Section 1 credits as defined by the Maintenance ofCertification program of the Royal College of Physicians and Surgeons of Canada. This program has been reviewed and approved byUBC Division of Continuing Professional Development. Each physician should claim only those credits he/she actually spent in theactivity.

EXCEMED adheres to the principles of the Good CME Practice Group (gCMEp)

2

Scientific organisers

Robert CarruthersDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Anthony TraboulseeDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

EXCEMED designed this programme in partnership with theMS and NMO Center of the University of British Columbia(UBC), Vancouver, Canada

3

Share your opinion with usWe are always looking for ways to bring our educational activities to the next level and meet your needs as a healthcarepractitioner.

You will be asked to answer a real-time survey during this event, followed by a post-event online survey to find out if theexperience met your educational expectations. Your views also help us tailor future initiatives.

Thank you for taking the time to participate.

Faculty members

4

Jason BartonDepartments of Medicine (Neurology), Ophthalmology and Visual Sciences, Psychology University of British ColumbiaVancouver, BC, Canada

Nancy BogleResearch NurseMultiple Sclerosis Clinical Trials GroupDepartment of Medicine University of British ColumbiaVancouver, BC, Canada

Robert CarruthersDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Stacy ElliottSexual MedicineDepartments of Psychiatry and Urologic SciencesUniversity of British ColumbiaVancouver, BC, Canada

Mark S. FreedmanMultiple Sclerosis Research UnitThe Ottawa HospitalOttawa, Canada

Kelly GrantB.E. Kelly GrantCRA West Vancouver, Canada

Lesley HouleSexual Health ClinicianGF Strong Rehab Centre & Blusson Spinal Cord CentreVancouver, BC, Canada

Shannon KolindDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Tanja KuhlmannInstitute of NeuropathologyUniversity Hospital MünsterMünster, Germany

David LiDepartment of RadiologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Katrina McMullenDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Ana- Luiza SayaoDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Anthony TraboulseeDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Carles Vilariño-GüellDepartment of Medical GeneticsFaculty of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Dean M. WingerchukMultiple Sclerosis CenterDepartment of NeurologyMayo ClinicScottsdale, USA

Ann YehDivision of Neurology The Hospital for Sick ChildrenToronto, ON, Canada

V. Wee YongHotchkiss Brain Institute and Departments of Clinical Neurosciences and OncologyUniversity of CalgaryCalgary, Canada

Scientificprogramme

Scientific programme

08.15 Breakfast

08.45 EXCEMED Opening

09.00 Introduction welcome to UBC HospitalMS/NMO Centre and introduction to Day 1Anthony Traboulsee (Canada)

Real-time survey

09.30 KNS1: Pathology of progression and repairTanja Kuhlmann (Germany)

10.30 Coffee break

11.00 KNS2: Stem cells in MSMark S. Freedman (Canada)

12.00 KNS3: Applied immunologyV. Wee Yong (Canada)

13.00 Working lunch

14.00 MRI Snapshots / Case studies

11.00 S1: Establishing an early diagnosisRobert Carruthers and David Li (Canada)

12.00 CS1: MRI Diagnostic Red FlagsAnthony Traboulsee (Canada)

S2: Advanced MRIShannon Kolind (Canada)

Discussion

6

16.00 L1: Genetics of MSCarles Vilariño-Güell (Canada)

17.00 Visit of Djavad Mowafaghian Centre for BrainHealth premises

17.45 End of the first day

18.00 Working dinner at Djavad Mowfaghian Centrefor Brain Health - 3rd Floor, A-B & C

Monday, 6 July 2015

Chairpersons: Robert Carruthers and Anthony Traboulsee (Canada)

MS BasicsDay 1

Legend:

L : Lecture; KNS : Key Note Speech; S : Snapshot CS : Case Studies PD : Panel Discussion

08.15 Breakfast

08.45 Introduction to Day 2Robert Carruthers (Canada)

09.00 CS2: Therapeutic decision making in MSAna-Luiza Sayao (Canada)

10.00 PD1: Panel discussion on: Shared decision making - A patient’sperspectiveNancy Bogle and Robert Carruthers (Canada)

11.00 Coffee break

11.30 L2: PML Diagnosis, Risk Stratification andManagementRobert Carruthers and David Li (Canada)

12.30 MRI in clinical practice

S3: Standardized protocolDavid Li (Canada)

S4: Routine monitoring of MSAnthony Traboulsee (Canada)

S5: Brain atrophy monitoringDavid Li (Canada)

Discussion

13.30 Working lunch

14.15 Group picture

14.30 S6: Sexual health in MSStacy Elliott and Lesley Houle (Canada)

15.00 L3: Neuro-opthalmology: what neurologistsneed to know about the eyes Jason Barton (Canada)

7

15.45 S7: High efficacy infusion based therapies in MSNancy Bogle and Anthony Traboulsee (Canada)

16.15 S8: How to set up and run a clinical trial unitKelly Grant and Anthony Traboulsee (Canada)

16.40 S9: Pregnancy in MSAna-Luiza Sayao (Canada)

17.15 End of the second day

Tuesday, 7 July 2015

Chairpersons: Robert Carruthers and Anthony Traboulsee (Canada)

MS Clinical PracticeDay 2

08.15 Breakfast

08.45 Introduction to Day 3Anthony Traboulsee (Canada)

09.00 KNS4: NMO update & 2015 Diagnostic CriteriaDean M. Wingerchuk (United States)

10.00 KNS5: Bridging MS and NMO: lessons frompediatric Acute Demyelinating SyndromesAnn Yeh (Canada)

11.00 Coffee break

11.30 L4: Acute management of NMO relapsesAnthony Traboulsee (Canada)

8

12.00 L5: NMO Preventative therapyRobert Carruthers (Canada)

12.45 S10: International collaborations in NMOKatrina McMullen (Canada)

13.15 Course wrap-upAnthony Traboulsee (Canada)

Revisiting real-time survey

13.30 End of the live educational course

Closing lunch

Wednesday, 8 July 2015

Chairpersons: Robert Carruthers and Anthony Traboulsee (Canada)

NMO UpdateDay 3

Faculty Disclosure Statement

9

The following faculty have provided no information regarding significant relationship with commercial supporters and/or as of 26June 2015. Jason BartonMark S. FreedmanKatrina McMullenDean M. Wingerchuk

In accordance with the Committee on Accreditation of Continuing Medical Education (CACME) Standards for Commercial Support, allfaculty participation in these programmes are expected to disclose to the programme audiences any real or apparent conflict of interestrelated to the content of their preparation.

NameAffiliations, financial or otherwise, with a commercial organization that may have a direct orindirect connection to the content of my presentation.

Nancy Bogle Nothing to disclose.

Robert Carruthers Declared to be/have been part of Roche, Genzyme, Novartis and Teva clinical trials in the last twoyears, declared the ownership of Dr. R. Carruthers Neurology Inc. and declared his wife performed aphase 1 trial with Genentech.

Stacy Elliott Declared to be member of Abbott’s and Lilly’s advisory board and Speakers’ bureau.

Kelly Grant Declared the receipt of grant from PPDI and the receipt of a Research Organization contract asClinical Research Associate from Quintiles.

Lesley Houle Nothing to disclose.

Shannon Kolind Declared the receipt of honoraria, consultation fees and research grants from Roche and Genzyme.

Tanja Kuhlmann Declared to be member of Genzyme Neuroprotection in MS Advisory Board Meeting in June 2014.Declared the receipt of honoraria and consultation fees from Novartis, Biogen Idec Canada. Shedeclared the receipts of Grants from the German Research Foundation and the Hetie Foundation.

David Li Declared to be member of Opexa, Novartis, Nuron, Roche advisory board, declared the receipt ofresearch grants from Genzyme, Roche and Merck Serono . He declared to be/have been part ofNuron, Perceptive and Sanofi clinical trials in the last two years. He declared the receipt of honorariaand consultation fees from Vertex Pharmaceuticals.

Ana- Luiza Sayao Declared to be member of Roche, Teva, Merck Serono, Biogen, Novartis and Genzyme Advisory boardand Speakers’ bureau. She declared to have taken part of an MS clinic’s clinical trial and declared thereceipt of honoraria from Roche, Teva, Merck Serono, Biogen, Novartis and Genzyme.

Anthony Traboulsee Declared to be member of Roche Clinical Trial Steering Committee, to be member of Sanofi andGenzyme speakers bureau. He declared to be/have been part of Roche, Biogen, Genzyme clinicaltrials in the last two years. Declared the receipt of honoraria from Teva Innovation, EMD Serono,Sanofi and Genzyme. He declared to be involved in the design of clinical studies concerning the use ofproducts manufactured Roche and Genzyme and he declared to have relationships with the followinggovernment agencies, regulatory bodies, and not‐for‐profit agencies: Canadian Institute for HealthResearch, MS Society of Canada.

Carles Vilariño-Güell Declared the receipt of research grants from Novartis Pharmaceuticals.

Ann Yeh Nothing to disclose.

V. Wee Yong Declared to be member of Teva Neuroscience Speakers’ bureau and the receipt of honoraria andconsultation fees from Teva, Biogen Idec, Genzyme and EMD Serono.

Biographies

11

Jason Barton obtained his MD from the University of British Columbia in 1984, where he completed a neurology residency in 1990.He was a fellow in neuro-ophthalmology at the University of Iowa from 1990 to 1991 and the University of Toronto from 1991 to 1995,and obtained his PhD from the University of Toronto in 1996. He was assistant and then associate professor of neurology at HarvardMedical School, and director of neuro-ophthalmology at the Beth Israel Deaconess Medical Center from 1996 to 2004. Since 2004he has been director of clinical neuro-ophthalmology at Vancouver General Hospital. He is currently professor, Canada ResearchChair and Marianne Koerner Chair in Brain Diseases, in neurology, ophthalmology and visual sciences at the University of BritishColumbia. His research is focused on cortical processing of vision, in particular high-level object perception, such as face and wordrecognition, and also on the use of saccadic eye movements to explore issues of cognitive control. He has published 2 books, 51chapters, and 167 research articles. He received the Francis McNaughton Award from the Canadian Neurological SciencesFederation, the Young Investigator Award from the North American Neuro-ophthalmology Society, the Norman Geschwind Award inBehavioural Neurology from the American Academy of Neurology, and the 2009 Distinguished Achievement Award for OverallExcellence from the UBC faculty of medicine. In general, though, he would rather be out cycling.

Jason BartonDepartments of Medicine (Neurology), Ophthalmology and Visual Sciences, Psychology University of British ColumbiaVancouver, BC, Canada

Nancy Bogle is a graduate of the BSN Nursing program at UBC following years of study of a BA at Acadia University in Wolfville,Nova Scotia. Aside from a short stint to explore Community Health work and Pediatric Neurology, the balance of her career has beenin the area of MS. Nancy first came to the UBC Clinic in 1995 and was involved in the initiation of the Special Therapies Program forthe first approved disease modifying therapies in MS. In late 1996, Nancy moved over to the area of MS Research at the UBC Clinicand has remained there since with the occasional day in the UBC MS Clinic. Nancy is a published author of a paper on PsychologicalDeterminants as a factor to Coping with MS, a co author on an article for Nursing specialization in MS for the International MS Orderof Nurses and a previous presenter at a plenary session of The Canadian Neurological Nurses Association, 1999 and a posterpresentation of the MS Consortium in 2000. Nancy considers the ability to work with persons and their families with MS a privilege.

Nancy BogleResearch NurseMultiple Sclerosis Clinical Trials Group, Department of Medicine University of British Columbia, Vancouver, BC, Canada

Biographies

12

Robert Carruthers joined UBC Staff in August 2014. He graduated from Tulane School of Medicine in 2008 and then completed hisinternship at Massachusetts General Hospital and residency at Brigham and Women’s Hospital and Massachusetts GeneralHospital. His two year Multiple Sclerosis Fellowship at Brigham and Women’s Hospital was funded by a grant from the NationalMultiple Sclerosis Society and included an equal mix of research and clinical training. His interests include clinical trial work andoptimizing clinical care in Multiple Sclerosis, Neuromyelitis Optica and other neuro-immunologic disorders.

Robert CarruthersDivision of Neurology, Department of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Stacy Elliott is a Sexual Medicine Physician whose interests lie in the sexual and reproductive consequences of medical or surgicalproblems, particularly neurological disability. She is a Clinical Professor in the Departments of Psychiatry and Urologic Sciences,and PI and Faculty member at International Collaboration of Repair Discoveries (ICORD), University of British Columbia. She is theMedical Manager of the BC Center for Sexual Medicine, Co-Director for the Vancouver Sperm Retrieval Clinic, sexual medicineconsultant to the Men’s Health Initiative , the Prostate Cancer Supportive Care program at the Prostate Center, and the GF StrongSexual Rehabilitation Service in Vancouver B.C. She is the current Past Chair of the Canadian Male Sexual Health Council, and aninvited member to the prestigious International Consensus of Sexual Medicine slated for June 2015. She participates on severalnational and international academic committees and advisory boards. She teaches at the UBC Medical School for undergraduatesand post-graduates, is active in CME of her colleagues, and is the author of many peer-reviewed journal articles and book chapters.Dr. Elliott is an internationally recognized expert in sexual rehabilitation and fertility following spinal cord injury, and in 2012, receivedthe QE II Jubilee medal for her work.

Stacy ElliottSexual MedicineDepartments of Psychiatry and Urologic SciencesUniversity of British Columbia, Vancouver, BC, Canada

13

Mark S. Freedman is currently professor of medicine in the field of neurology at the University of Ottawa, as well as director of theMultiple Sclerosis Research Unit at the Ottawa Hospital, General Campus and a Senior Scientist at the Ottawa Hospital ResearchInstitute. A graduate of the University of Toronto, Dr. Freedman holds his Masters Degree in Molecular Neurochemistry andcontinued his postgraduate work specializing in neurology and neuroimmunology. His specialized training took him to the WeizmannInstitute of Science, Israel; The National Hospital, Queen Square, London UK, as well as the Montreal Neurological Institute, wherehe subsequently was an Assistant Professor. He holds his specialist certification in Quebec CSPQ and all of Canada FRCP(C) and isa Fellow of both the American Neurological Association (FANA) and the American Academy of Neurology (FAAN). Dr. Freedman haspublished over 250 pieces, including articles, books, book chapters and abstracts and has been invited to give hundreds of lecturesand presentations nationally and internationally. His extensive research includes the area of molecular neurochemistry, cellularimmunology, neuroimmunology and clinical studies in MS. He is currently holding peer reviewed and industry related funding fortranslational research investigating immune mechanisms of damage in multiple sclerosis, with particular interest in the role ofgamma-delta T-cells. He is also the lead investigator in the Canadian Bone Marrow Transplant Study in MS and co-chair of theInternational Mesenchymal Stem Cell Transplantation Study Group. Dr. Freedman has over 25 years of experience in themanagement of patients with multiple sclerosis and has been the principal investigator on numerous clinical trials with newtherapeutic agents for MS. He has experience from serving on several research study steering committees as well as data safetymonitoring boards. He serves on the editorial boards for several journals including the Multiple Sclerosis Journal. He has alsoserved on several national and international committees and is currently the Treasurer of the Americas Committee for Treatmentand Research in MS (ACTRIMS).

Mark S. FreedmanMultiple Sclerosis Research UnitThe Ottawa HospitalOttawa, Canada

Kelly Grant, RN, BA, CCRA, after completing nursing school at UBC and obtaining a BA Psych, Kelly also completed post-graduatecourse work in neurosciences, research design and statistics. Kelly has worked many years as a study nurse/coordinator, a nationalclinical trial coordinator, and as a monitor/CRA since 1996. She became an independent consultant CRA in 1997 and obtained ACRP(Association of Clinical Research Professionals) CCRA certification. She has worked for the pharmaceutical industry, for CROs andfor government-funded trials in many areas. Her greatest interest remains with neurology clinical trials.

Kelly GrantB.E. Kelly GrantCRA West Vancouver, Canada

Biographies

14

Lesley Houle graduated from the Kwantlen College Nursing Program in 1993. She has been nursing for 20 years and has spent amajority of time working with people with disabilities and chronic illness in rehabilitation. Lesley currently is a Sexual Health Clinicianat GF Strong Rehab Centre and the Blusson Spinal Cord Centre providing sexual health education, teaching, and support to clients,their families and health care professionals as it relates to illness and disability.

Lesley HouleSexual Health ClinicianGF Strong Rehab Centre & Blusson Spinal Cord CentreVancouver, BC, Canada

Shannon Kolind completed her graduate studies in Physics at the University of British Columbia under the supervision of Dr. AlexMacKay, developing quantitative MRI techniques specific to myelin content. She then took up a Postdoctoral Fellowship from the MSSociety of Canada at the University of Oxford with Drs. Sean Deoni and Heidi Johansen-Berg. There she further developed myelin-specific imaging, as well as other advanced MRI techniques, and applied them to the study of several clinical applications. In theDepartment of Neuroimaging at the Institute of Psychiatry, King’s College London, she was able broaden the range of clinicalapplications for these techniques. She then returned to the University of British Columbia to take up a Michael Smith Foundation forHealth Research Postdoctoral Fellowship, changing departments (from Physics to Medicine (Neurology)) to work directly with thedirector of the UBC MS Clinic and Research Centre, Dr. Anthony Traboulsee. There she has focused on the application of advancedMRI techniques including myelin water imaging in clinical trials for diseases such as MS.

Shannon KolindDivision of Neurology, Department of MedicineUniversity of British ColumbiaVancouver, BC, Canada

15

Tanja Kuhlmann studied medicine at the University of Göttingen, Germany where she received her medical degree in 1998. Shespecialized in neuropathology and worked as medical resident and research fellow in different neuropathological departments inGermany and as a post-doc at McGill, Canada in the research groups of Dr. Jack Antel and Dr. Alan Peterson. In 2008, she becamesenior consultant and associate professor for neuropathology at the University Hospital Münster, Germany. Her key researchinterests are mechanisms leading to oligodendroglial and axonal pathology in multiple sclerosis lesions. She has published severalpublications in well known international journals on the topic of MS pathology, especially on oligodendroglial loss and remyelination.

Tanja KuhlmannInstitute of NeuropathologyUniversity Hospital MünsterMünster, Germany

Professor of Radiology and Associate Member in Neurology at the University of British Columbia (UBC) and Director of the UBCMS/MRI Research Group. He was formerly Head of Radiology at the UBC Hospital and Interim Head, Department of Radiology,University of British Columbia. After obtaining his medical degree and radiology residency at UBC, which included additional trainingin nuclear medicine at Harvard Medical School and body CT at University of California (San Francisco), he did postgraduate studiesin MRI at the Royal Postgraduate Medical School (London). His primary research interest is the application of MR techniques in thestudy of patients with multiple sclerosis.

David LiDepartment of RadiologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Biographies

16

Ana-Luiza Sayao, BSc, MD, FRCPC, is currently a Neurologist at St. Paul’s Hospital and the University of British Columbia MultipleSclerosis Clinic. She completed her residency training at UBC and Royal College board certification in Neurology in 2009. Highlightsof her residency include an elective in Oxford England, where she studied history of Multiple Sclerosis, and wining the Ludmila andHenry Zeldowicz award for Neurology Resident Research in MS. She then completed a Fellowship in Multiple Sclerosis at UBC in2010 with a research focus on clinical epidemiology and evaluating patients with Benign MS, specifically assessing cognitive,psychosocial, quality of life and MRI changes in this unique group of MS patients. After a few years of general Neurology and MSpractice, she completed a mini-Fellowship in Electroencephalography in 2014 and just successfully passed the Canadian EEGcertification exam. She is actively involved in education of Neurology residents on communication skills, Multiple Sclerosis andgeneral aspects of Clinical Neurology. She is the adult Neurology Lead in the BC Pediatric Transition Care Project where she andcolleagues are creating transition care plans for young persons with neurological disorders including Multiple Sclerosis and otherNeuro-inflammatory conditions. She is currently an Assistant Clinical Professor at UBC.

Ana- Luiza SayaoDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Katrina McMullen completed her PhD in clinical neuroscience at Kings College London before moving to Vancouver to undertake apostdoctoral fellowship under Dr Traboulsee and Dr Kolind at UBC. Her research focuses on understanding the cognitive andpsychological symptoms in MS and NMO and how they relate to changes in neurobiology observed using structural and functionalimaging. She is currently the manager of the NMO Clinic and Research Program at UBC, working with Dr Traboulsee and DrCarruthers to develop a program of research investigating the causes and treatment of NMO.

Katrina McMullenDivision of NeurologyDepartment of MedicineUniversity of British ColumbiaVancouver, BC, Canada

17

Vilariño-Güell is an expert molecular geneticist who has dedicated his career to the identification and understanding of geneticcomponents of human diseases. His focus has been on the identification of mutations leading to familial forms of neurologicaldisease, the analysis of complex epidemiological data in ethnically distinct populations, and to identify susceptibility variants actingas early precursors of disease development. In his relatively short career, he has published over 70 articles in many prestigiousjournals including New England Journal of Medicine, Nature Genetics, and American Journal of Human Genetics resulting in an h-index of 18 and over a thousand citations (Web of Science, September 4, 2014). Highlights include the identification of DCTN1mutations for Perry syndrome, MEIS1 for restless legs syndrome, VPS35 and EIF4G1 for Parkinson disease, DNAJC13 mutations forParkinson disease and essential tremor, and more recently NR1H3 for progressive multiple sclerosis. By the end of 2012 Dr. Vilariño-Güell obtained a Canada Research Chair award and started an independent research program at the University of British Columbia.The main goal of this research program is to molecularly define the etiology of multiple sclerosis and to develop knowledge-basedapproaches to improve diagnostic accuracy and the generation of novel therapeutics aimed at treating the underlying molecularcauses of disease. These goals are in line with Dr. Vilariño-Güell’s experience, research approaches and successful achievementsin other complex multifactorial neurological diseases. This goal will be achieved by identifying pathogenic mutations leading tomultiple sclerosis in multi-incident families, a program already funded by the Canadian Institutes of Health Research; and theidentification of risk alleles and genetic modifiers of disease course, a yet to be completed pilot has been funded by NovartisPharmaceuticals Canada. The identification of functionally relevant genetic determinants in multiple sclerosis will define themolecular etiology of disease, provide an immediate means for accurate risk evaluation and early disease diagnosis, reveal noveltargets and biomarkers for therapeutic intervention trials, highlight direct avenues for the creation of etiologic in vitro, ex vivo and invivo models, and provide the rationale for high throughput assays to identify novel therapeutics to better treat this common disease.

Carles Vilariño-GüellDepartment of Medical GeneticsFaculty of Medicine, University of British ColumbiaVancouver, BC, Canada

Anthony Traboulsee is an Associate Professor and Research Chair of the MS Society of Canada at the University of British Columbiain Vancouver, Canada. He is the Director of the MS/NMO Clinic and Clinical Trials Research Group at UBC Hospital. His researchfocus is on clinical trial design, the development of practice guidelines for the use of MRI in the management of MS, establishingadvanced MRI imaging outcomes in Multiple Sclerosis, and the treatment of Neuromyelitis Optica.

Anthony TraboulseeDivision of Neurology, Department of MedicineUniversity of British ColumbiaVancouver, BC, Canada

Biographies

18

Dean M. Wingerchuk, MD, MSc, FRCP(C) is Professor of Neurology at Mayo Clinic in Scottsdale, Arizona. He also serves as Chair ofthe Mayo Clinic Division of Multiple Sclerosis and Autoimmune Neurology. He obtained his medical degree at the University ofSaskatchewan, Saskatoon, Canada, and completed a neurology residency at Mayo Clinic in Rochester, MN. He completed successivefellowship programs in clinical neuroimmunology at the Mayo Clinic and at the University of Western Ontario, London, Canada. Healso completed a Master degree program in Clinical Epidemiology and Health Research Methodology at McMaster University inHamilton, Canada. Dr. Wingerchuk’s clinical and research interests focus on multiple sclerosis, neuromyelitis optica, and relateddisorders. He is currently the principal investigator for two therapeutic studies for neuromyelitis optica. Dr. Wingerchuk also co-directs the Mayo Clinic’s MERIT Center, a multidisciplinary evidence-based clinical practice educational and research program andis co-Editor-in-Chief of The Neurologist.

Dean M. WingerchukMultiple Sclerosis CenterDepartment of NeurologyMayo ClinicScottsdale, USA

Ann Yeh is a graduate of Harvard University, received an MA from McGill University (Montreal, Canada), and her MD at McMasterUniversity (Hamilton, ON). She completed pediatrics training at McMaster University and pediatric neurology training at SUNYBuffalo, where she developed and co-directed the Pediatric MS and Demyelinating Disorders Center of Excellence. She is currentlyan Associate Professor of Pediatrics (Neurology) at the Hospital for Sick Children, University of Toronto, Canada, where she is thedirector of the MS and Demyelinating Disorders Clinic. She is the director of the pediatric neurology training program at theUniversity of Toronto. Her research interests are in visual and neuro-cognitive outcomes in pediatric demyelinating conditions,rehabilitative interventions for this population, as well as therapies for pediatric MS.

Ann YehDivision of NeurologyThe Hospital for Sick ChildrenToronto, ON, Canada

19

V. Wee Yong is a Professor at the Hotchkiss Brain Institute and the Departments of Clinical Neurosciences and Oncology at TheUniversity of Calgary. He holds the Canada Research Chair in Neuroimmunology. Dr. Yong co-directs the Multiple Sclerosis (MS)NeuroTeam of the Hotchkiss Brain Institute, providing the basic science leadership, and he directs the Alberta endMS TrainingNetwork. Dr. Yong received his Ph.D. from the University of British Columbia, Vancouver, and started his faculty appointment at theMontreal Neurological Institute, McGill University, in 1989. He located to Calgary in 1996. Dr. Yong’s research interests lie in the areaof neuroimmunology, neuroprotection and CNS regeneration, and his projects have been guided by MS, spinal cord injury andmalignant gliomas. Dr. Yong has published 240 peer-reviewed manuscripts and his research has been translated into clinical trialsin MS and spinal cord injury. His work has been cited over 13,000 times by other authors in scientific publications. Dr. Yong is theimmediate past chair of the Medical Advisory Committee of the MS Society of Canada; this and other volunteer activities resulted inDr. Yong receiving the Queen’s Golden Jubilee Year Medallion. Dr. Yong is on the editorial board of 7 international journals. He is thecurrent President of the International Society of Neuroimmunology. Dr. Yong is an elected fellow of both the Canadian Academy ofHealth Sciences (2010) and the Royal Society of Canada (2014), which represent top honors for those working in the medical andacademic sciences, respectively.

V. Wee YongHotchkiss Brain Institute and Departments of Clinical Neurosciences and Oncology University of Calgary, Calgary, Canada

Learningobjectives

KNS3. Applied Immunology

V. Wee Yong Hotchkiss Brain Institute and Departments of Clinical Neurosciences and Oncology University of Calgary, Calgary, Canada

1. Loss of regulatory function in MS involves both B and T cells

2. MS therapies are targeted at specific immunological pathways

3. Contrast the immunology of progressive MS and relapsing MS

21

KNS1. Pathology of progression and repair

Tanja KuhlmannInstitute of Neuropathology, University Hospital Münster, Münster, Germany

1. Permanent disability in MS is a consequence of axonal loss

2. The CNS has an innate capacity to remyelinate

3. Progression in MS occurs when there is a loss of repair and excelarated neuronal loss

KNS2. Stem cells in MS

Mark S. Freedman Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada

1. To learn about potential sources of stem cells for clinical use in transplantation

2. To become familiar with current attempts in utilizing stem cells for treatment in MS

3. To be able to differentiate between stem cell transplantation and bone marrow transplantation used for MS treatment

S2. Advanced MRI

Shannon Kolind Division of Neurology, Department of Medicine, University of British Columbia Vancouver, BC, Canada

1. Gain an overview of novel and advanced MRI techniques

2. Understand the relative sensitivity and specificity of these MRI techniques to various biological and pathological features

3. Consider the use of MRI beyond anatomical assessment in clinical trials for neurological disease therapies

22

S1. Establishing an early diagnosis

Robert CarruthersDivision of Neurology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

David LiDepartment of Radiology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. Understand the role of MRI in helping to diagnose MS in patients with CIS

2. Understand the importance and value of an earlier diagnosis of MS

3. To be familiar with and be able to use the 2010 McDonald criteria for the diagnosis of MS

MRI Snapshots / Case Studies

CS1. MRI Diagnostic Red Flags

Anthony Traboulsee Division of Neurology, Department of Medicine, University of British Columbia Vancouver, BC, Canada

1. Brain MRI is highly sensitive for detecting any pathology but relatively non specific

2. Spinal cord MRI can aid in the differential diagnosis of challenging cases

2. Contrast enhancement can distinguish MS from some rare mimics

Learning objectives

CS2. Therapeutic decision making in MS

Ana-Luiza Sayao Division of Neurology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. To provide a current overview of Multiple Sclerosis (MS)

2. To review the course and management issues of a representative patient with RRMS

3. To review the therapeutic landscape in MS, including both current and emergent treatments

23

L1. Genetics of MS

Carles Vilariño-Güell Department of Medical Genetics, Faculty of Medicine, University of British ColumbiaVancouver, BC, Canada

1. Genetic contribution to MS

2. Risk alleles and pathogenic variants implicated in MS

3. Application of genetic discoveries

Visit of Djavad Mowafaghian Centre for Brain Health premises

1. Introduction to Djavad Mowafaghian Centre for Brain Health and multi-disciplinary approach to MS Clinic

2. Tour of MS Clinic, Infusion Suite and Research Labs to show benefit of integrated neuroscience, integrating patient care andcutting-edge research

3. Show through integration aim is to speed up delivery of promising treatments and offer best care to patients

L2. PML Diagnosis, Risk Stratification and Management

Robert CarruthersDivision of Neurology, Department of Medicine, University of British Columbia Vancouver, BC, Canada

David LiDepartment of Radiology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. Describe how risk factors for PML have changed in recent decades

2. Describe the approach to diagnosing PML recommended by the AAN Neuro Infectious Disease Section

3. Discuss the treatment approach for PML and PML/IRIS

24

PD1. Panel Discussion on:Shared decision making - A patient’s perspective

Nancy BogleResearch Nurse, Multiple Sclerosis Clinical Trials Group, Department of Medicine University of British Columbia, Vancouver, BC, Canada

Robert CarruthersDivision of Neurology, Department of Medicine, University of British Columbia Vancouver, BC, Canada

1. Identifying patient and care giver therapeutic goals.

2. Compare and contrast paternalism to shared decision making in MS therapeutics

3. How to balance risk versus benefit when discussing therapeutic options

Learning objectives

25

S5. Brain Atrophy Monitoring

David LiDepartment of Radiology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. To be updated on the importance of brain atrophy and monitoring of brain atrophy in patients with MS

2. To be introduced to methodological considerations for quantitative brain volume measurements

3. To become familiar with factors that affect changes in brain volume

S3. Standardized Protocol

David LiDepartment of Radiology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. To understand the need for a standardized MRI examination

2. To learn the details of a standardized MRI examination

3. To learn and apply the MRI guidelines for the use of a standardized MRI examination in the diagnosis and follow-up of patientswith MS

MRI in Clinical Practice

S4. Routine Monitoring of MS

Anthony Traboulsee Division of Neurology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. Routine brain MRI can detect clinically silent disease activity

2. Detecting ongoing MRI activity can be helpful in therapeutic management

L3. Neuro-ophthalmologyWhat neurologists need to know about the eyes

Jason BartonDepartments of Medicine (Neurology), Ophthalmology and Visual Sciences, Psychology University of British Columbia, Vancouver, BC, Canada

1. Review the various ways multiple sclerosis and NMO affected the afferent visual pathway

2. Review the ocular motor manifestations of multiple sclerosis and their diagnosis

S7. High efficacy infusion based therapies in MS

Nancy BogleResearch Nurse, Multiple Sclerosis Clinical Trials Group, Department of Medicine University of British Columbia, Vancouver, BC, Canada

Anthony TraboulseeDivision of Neurology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. High efficacy options for relapsing MS

2. Clinical indications for escalating therapy

3. Managing an infusion program

26

S6. Sexual health in MS

Stacy ElliottSexual Medicine, Departments of Psychiatry and Urologic Sciences University of British Columbia, Vancouver, BC, Canada

Lesley HouleSexual Health Clinician, GF Strong Rehab Centre & Blusson Spinal Cord CentreVancouver, BC, Canada

1. Describe the most common sexual problems seen in these populations

2. Utilize the Sexual Health Framework to categorize multidisciplinary assistance

3. Summarize current therapies available to manage sexual dysfunctions

4. Demonstrate the approach to sexual health questioning for clinicians

Learning objectives

KNS4. NMO update & 2015 Diagnostic Criteria

Dean M. WingerchukMultiple Sclerosis Center, Department of Neurology, Mayo ClinicScottsdale, USA

1. NMO is an astrocytopathy

2. 2015 Diagnostic Criteria

27

S8. How to set up and run a clinical trial unit

Kelly Grant B.E. Kelly Grant, CRA West Vancouver, Canada

Anthony TraboulseeDivision of Neurology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. Basic makeup of a clinical trial team

2. Monitor's view from the trenches

3. Basic regulatory considerations

S9. Pregnancy in MS

Ana-Luiza SayaoDivision of Neurology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. To review pregnancy related issues in patients with multiple sclerosis

2. To review multiple sclerosis medication safety in pregnancy

L4. Acute management of NMO relapses

Anthony TraboulseeDivision of Neurology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. Identify role of oral versus high dose steroids for NMO relapse

2. Criteria for escalation to apheresis (plasma exchange)

3. Discuss controversies around chemotherapy induction

L5. NMO Preventative therapy

Robert CarruthersDivision of Neurology, Department of Medicine, University of British Columbia Vancouver, BC, Canada

1. Understand existing data underlying commonly used therapies in NMO and its limitations

2. Become familiar with mechanisms of action of compounds being evaluated in clinical trials for patients with Neuromyelitis optica

28

KNS5. Bridging MS and NMO: lessons from pediatric Acute Demyelinating Syndromes

Ann YehDivision of Neurology, The Hospital for Sick Children, Toronto, ON, Canada

1. Risk of MS and NMO after pediatric ADS

2. Treatment of pediatric ADS, MS, NMO

Learning objectives

29

S10. International Collaborations in NMO

Katrina McMullenDivision of Neurology, Department of Medicine, University of British ColumbiaVancouver, BC, Canada

1. NMO is a global disease

2. Collaborative international research is required to find the cause and cure (CIRCLES)

NOTES

NOTES

All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activitiesare permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and donot represent an endorsement or recommendation on the part of EXCEMED. Merck Serono, the biopharmaceutical division of Merck KgaA, Germany.

Improving the patient's life through medical educationwww.excemed.org

EXCEMED - Excellence in Medical Education Headquarters14, Rue du Rhône - 1204 Geneva, SwitzerlandRepresentative OfficeSalita di San Nicola da Tolentino 1/b - 00187 Rome, ItalyT +39 06 420413 1 - F +39 06 420413 677

Copyright © EXCEMED, 2015. All rights reserved.